Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line <scp>EGFR</scp> tyrosine kinase inhibitors: A network meta‐analysis of real‐world evidence

Chang, Huang‐Chih; Huang, Kuo‐Tung; Tseng, Chia‐Cheng; Chen, Yu‐Mu; Lai, Chien‐Hao; Chang, Yu‐Ping; Chen, Yung‐Che; Chuang, Hung‐Yi; Wang, Chin‐Chou

doi:10.1111/1759-7714.15112

Cited by 2 publications

(1 citation statement)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Afatinib, an irreversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), is the first-line treatment for nonsmall-cell lung cancer (NSCLC) with EGFR mutation[ 1 ] and a promising combinatory therapy for metastatic nasopharyngeal carcinoma (NPC) with EGFR overexpression. [ 2 ] EGFR is distributed over corneal and periocular regions.…”

Section: Introductionmentioning

confidence: 99%

Bilateral keratitis associated with afatinib therapy

Liu,

Lin,

Sun

et al. 2024

Taiwan Journal of Ophthalmology

View full text Add to dashboard Cite

This case discussed a significant ocular side effect, bilateral keratitis, which could be induced by afatinib, an irreversible epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). We explored the disease progression of a 52-year-old, stage IV nasopharyngeal carcinoma male patient, who was under afatinib treatment and had experienced progressive bilateral eye dryness and tenderness on increasing afatinib from 40 mg every other day to 40 mg daily. Clinical examination noted bilateral visual acuity reduction, diffuse superficial punctate keratopathy in the right eye, and a central epithelial defect in the left eye. Seidel test results were negative for both eyes, with no corneal infiltration, lagophthalmos, anterior chamber cell precipitation, or retinal lesion. Symptoms subsequently resolved after reducing the frequency of afatinib used, along with intensive ocular hydration. In summary, this case highlighted afatinib’s potential link to bilateral keratitis, and early afatinib dose adjustment with supportive medication could significantly reverse the condition.

show abstract

Section: Introductionmentioning

confidence: 99%

Bilateral keratitis associated with afatinib therapy

Liu,

Lin,

Sun

et al. 2024

Taiwan Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

Development and validation of an LC–MS/MS method for the determination of BLU-945, a fourth-generation EGFR tyrosine kinase inhibitor, in rat and mouse plasma: application to a pharmacokinetic study in rats

Oh,

Nguyen,

Maeng

2024

J Anal Sci Technol

View full text Add to dashboard Cite

BLU-945, a new-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is a potential drug candidate for the treatment of non-small-cell lung cancer (NSCLC) in patients with mutations that are resistant to previous generations of EGFR TKI. This compound has been investigated in preclinical and phase 1 dose-escalation studies that require a bioanalytical method for drug quantitation. In this study, an LC–MS/MS method was developed and validated for the quantitation of BLU-945 in rodent plasma and was applied to pharmacokinetic studies. The compound was extracted from plasma samples using a simple protein precipitation method. The method was validated in the linearity range of 1–1000 ng/mL with acceptable accuracy and precision, no matrix effects, and complete extraction recovery. BLU-945 was stable in the plasma quality control samples under various handling and storage conditions. The compound was stable after 4-h incubation in human, mouse, and rat plasma but was extensively metabolized in the microsomal fractions of these species. Furthermore, the validated analytical method was applied to a pharmacokinetic study in rats, revealing that BLU-945 had a high oral bioavailability range (55.91–105.6%) with a nonlinear pharmacokinetic profile up to an oral dose of 20 mg/kg. The validated bioanalytical method and findings of our study represent valuable assets for future investigations and clinical studies of BLU-945.

show abstract

Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of real‐world evidence

Cited by 2 publications

References 44 publications

Bilateral keratitis associated with afatinib therapy

Bilateral keratitis associated with afatinib therapy

Development and validation of an LC–MS/MS method for the determination of BLU-945, a fourth-generation EGFR tyrosine kinase inhibitor, in rat and mouse plasma: application to a pharmacokinetic study in rats

Contact Info

Product

Resources

About